This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignees: Crucell Switzerland Ag, Schweiz Serum & Impfinstitut Bern. Active years: 2008-2012.
Location History:
- Zurich, CH (2008)
- Ulm, DE (2010 - 2012)
Company Filing History:
Years Active: 2008-2012
Title: Frank Radecke: Innovator in RNA Virus Methodology
Introduction
Frank Radecke is a notable inventor based in Ulm, Germany. He has made significant contributions to the field of virology, particularly in the generation of nonsegmented negative-strand RNA viruses. With a total of 4 patents, Radecke's work has implications for vaccine development and gene therapy applications.
Latest Patents
Radecke's latest patents include innovative methodologies for generating nonsegmented negative-strand RNA viruses from cloned deoxyribonucleic acid (cDNA). These rescued viruses are designed for use as vaccines or as plasmids in somatic gene therapy applications. His inventions also encompass cDNA molecules that serve as tools in this methodology, along with helper cell lines that facilitate the direct rescue of such viruses. Measles virus (MV) is utilized as a model for other representatives of the Mononegavirales, particularly within the family Paramyxoviridae.
Career Highlights
Throughout his career, Frank Radecke has worked with several prominent companies, including Crucell Switzerland AG and Schweiz Serum & Impfinstitut Bern. His expertise in virology and innovative methodologies has positioned him as a key figure in the development of new therapeutic approaches.
Collaborations
Radecke has collaborated with notable professionals in his field, including Martin Billeter and Pius Spielhofer. These collaborations have further enhanced his research and contributions to virology.
Conclusion
Frank Radecke's innovative work in the field of RNA viruses has paved the way for advancements in vaccine development and gene therapy. His contributions continue to influence the scientific community and hold promise for future medical applications.